Considering the fact that cetuximab is a monoclonal antibody that specifically targets EGFR and competitively inhibits ligand binding, it is not unexpected that the patients with tumour expression of EGFR and low levels of competitive ligands showed better treatment outcome (Mendelsohn and Baselga, 2003). Here, EGFR is linked to neoplasm.